发现[c]芬丁衍生物对抗多药耐药性Mycobacterium结核病具有强烈活性
Yi Chu Liang1,2, Zhiqi Sun2, Chen Lu3,4
1Department of Microbiology and Immunology, University of British Columbia, Vancouver, Canada.
Microbiology spectrum
|October 3, 2024
概括
新型[c]衍生物 (BPD) 对耐药结核病 (TB) 菌株表现出强烈的活性. 这些化合物在体外,感染的巨细胞和小鼠中是有效的,为结核病药物发现提供了新的支架.
科学领域:
- 药用化学 医学化学
- 微生物学 微生物学
- 药物发现 药物发现 药物发现
背景情况:
- 由Mycobacterium tuberculosis (Mtb) 引起的结核病 (TB) 是全球主要的与细菌疾病相关的死亡原因.
- 目前的结核病治疗是漫长的,并且因药物耐药性增加而受到挑战,需要新的治疗药物.
- 多药耐药 (MDR) Mtb菌株构成重大威胁,迫切需要开发新的抗结核药物.
研究的目的:
- 设计和合成具有强大的抗Mtb活性的新型[c]丁衍生物 (BPDs).
- 评估这些BPD对各种Mycobacterium菌株的疗效,包括MDR Mtb.
- 调查BPD作为未来抗结核药物开发的支架的潜力.
主要方法:
- 合成了35种新的[c]丁衍生物 (BPD).
- 在体外对抗Mtb活性的评估,包括最小抑制度 (MIC90) 的确定.
- 在受感染的巨细胞和M. bovis BCG感染的小鼠模型中评估化合物活性.
- 对不复制的Mtb (NR-Mtb) 和临床MDR Mtb分离物的测试.
- 通过突变产生的抵抗机制的识别.
主要成果:
- 两种强效的BPDs,BPD-6和BPD-9,对多种Mycobacterium菌株表现出强大的抑制活性 (MIC90~2-10μM).
- BPD-6和BPD-9对Mycobacterium物种表现出选择性活性,对其他格拉姆阴性或格拉姆阳性细菌没有活性.
- 化合物有效降低了巨细胞中的Mtb存活率和小鼠肺中的M. bovisBCG负担.
- BPDs对非复制的Mtb表现出与利芬素相似的疗效,并抑制了多个MDR Mtb临床分离物.
- 鉴定出MMR排水是BPD-9的一个间接抵抗机制.
结论:
- 新型BPD对包括MDR Mtb菌株在内的Mycobacterium物种表现出强大和选择性的活性.
- BPD在临床前模型中表现出有效性,表明它们作为新型抗结核病药物候选者的潜力.
- 抗结核病药物的独特特异性和有效性表明了潜在的新型作用机制,为抗结核病药物发现提供了有前途的支架.
关键词:
结核病菌菌菌的结核病菌的结核病菌.抗菌素化合物是一种抗菌素化合物.二二二二二二二二二二二二多重耐药结核病是多重耐药的结核病.自然化合物 自然化合物不复制的细菌是不复制的细菌结核病是一种肺结核病.更多相关视频
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
10:24Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells
Published on: May 22, 2026
相关概念视频
Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
